- Trials with a EudraCT protocol (178)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
178 result(s) found for: Heart Failure AND Atrial Fibrillation.
Displaying page 1 of 9.
EudraCT Number: 2008-005248-17 | Sponsor Protocol Number: 1160.71 | Start Date*: 2008-11-20 | |||||||||||
Sponsor Name:Boehringer Ingelheim AB | |||||||||||||
Full Title: RELY-ABLE long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowle... | |||||||||||||
Medical condition: This is a study of the long term safety of dabigatran (intended indication: stroke prevention in patients with atrial fibrillation).Eligible patients received dabigatran during the RE-LY trial 1160... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) NL (Completed) FI (Completed) DE (Completed) DK (Completed) AT (Completed) GB (Completed) SK (Completed) FR (Completed) BE (Completed) HU (Completed) PL (Completed) CZ (Completed) IT (Completed) PT (Completed) BG (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-019791-73 | Sponsor Protocol Number: EFC11405 | Start Date*: 2010-07-22 | |||||||||||
Sponsor Name:Sanofi-aventis recherche & développement | |||||||||||||
Full Title: A randomized, double blind, placebo controlled, parallel group trial for assessing the clinical benefit of Dronedarone 400mg BID on top of standard therapy in patients with permanent atrial fibrill... | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) SE (Prematurely Ended) FR (Prematurely Ended) CZ (Prematurely Ended) ES (Completed) HU (Completed) BE (Prematurely Ended) SK (Prematurely Ended) DK (Prematurely Ended) GB (Prematurely Ended) FI (Prematurely Ended) AT (Prematurely Ended) DE (Completed) IT (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003836-35 | Sponsor Protocol Number: 2017-001-COPAF | Start Date*: 2018-08-17 | ||||||||||||||||
Sponsor Name:Population Health Research Institute | ||||||||||||||||||
Full Title: Colchicine For The Prevention Of Perioperative Atrial Fibrillation In Patients Undergoing Thoracic Surgery (COP-AF) | ||||||||||||||||||
Medical condition: Perioperative atrial fibrillation / atrial flutter after thoracic surgery | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) BE (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-003702-33 | Sponsor Protocol Number: RG_14-150 | Start Date*: 2015-01-23 | |||||||||||||||||||||
Sponsor Name:University of Birmingham | |||||||||||||||||||||||
Full Title: IMPRESS-AF: IMproved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation | |||||||||||||||||||||||
Medical condition: Atrial fibrillation with preserved left ventricular systolic function and normal levels of the brain natriuretic peptide. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002442-45 | Sponsor Protocol Number: AXAFA-AFNET5 | Start Date*: Information not available in EudraCT | ||||||||||||||||||||||||||
Sponsor Name:Kompetenznetz Vorhofflimmern e.V. [Atrial Fibrillation NETwork (AFNET)] | ||||||||||||||||||||||||||||
Full Title: Anticoagulation using the direct factor Xa inhibitor apixaban during Atrial Fibrillation catheter Ablation: Comparison to vitamin K antagonist therapy. | ||||||||||||||||||||||||||||
Medical condition: Atrial fibrillation catheter ablation | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) BE (Completed) DK (Completed) GB (Completed) NL (Completed) ES (Completed) AT (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-000055-41 | Sponsor Protocol Number: CV185-220 | Start Date*: 2013-08-09 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: Assessment of an Education and Guidance programme for Eliquis Adherence in Non-Valvular Atrial Fibrillation (AEGEAN) | |||||||||||||
Medical condition: Patients with Non-Valvular Atrial Fibrillation with at least one risk factor for stroke and indicated for oral anticoagulant. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) GB (Completed) ES (Completed) DE (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-011291-29 | Sponsor Protocol Number: RACE 3 | Start Date*: 2011-08-16 | |||||||||||
Sponsor Name:Interuniversity Cardiology Institute of the Netherlands (ICIN) | |||||||||||||
Full Title: Routine versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure: RACE 3 | |||||||||||||
Medical condition: atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003487-48 | Sponsor Protocol Number: F373280CA201 | Start Date*: 2013-02-25 | |||||||||||
Sponsor Name:PIERRE FABRE MEDICAMENT | |||||||||||||
Full Title: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure. | |||||||||||||
Medical condition: F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic h... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) HU (Completed) CZ (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018374-20 | Sponsor Protocol Number: 6517-CL-0020 | Start Date*: 2010-12-09 | |||||||||||
Sponsor Name:Cardiome UK Limited | |||||||||||||
Full Title: A Phase 3b Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Vernakalant Hydrochloride Injection in Patients with Recent Onset Symptomatic At... | |||||||||||||
Medical condition: Recent Onset Symptomatic Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005437-38 | Sponsor Protocol Number: D1250C00008 | Start Date*: 2007-03-07 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Controlled, Randomized, Parallel, Multicentre Study to Assess Safety and Tolerability of the Oral Direct Thrombin Inhibitor AZD0837, given as an Extended-release Formulation, in the Prevention of... | |||||||||||||
Medical condition: Paroxysmal, persistent or permanent nonvalvular atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) SE (Completed) HU (Completed) AT (Completed) DK (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000263-92 | Sponsor Protocol Number: 17-251 | Start Date*: 2018-05-28 | |||||||||||
Sponsor Name:CHU CAEN | |||||||||||||
Full Title: Spironolactone and perioperative atrial fibrillation occurrence in cardiac surgery patients: a multicenter randomized, double-blind study | |||||||||||||
Medical condition: Patients > 18 years referred for elective cardiac bypass graft (CABG) surgery ± aortic valve replacement (AVR) without any systolic heart failure or any mitral surgery associated | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000484-86 | Sponsor Protocol Number: 02022018 | Start Date*: 2019-01-16 | |||||||||||||||||||||
Sponsor Name:Rigshospitalet | |||||||||||||||||||||||
Full Title: DAN-WAR-D Danish Warfarin-Dialysis Study Safety and efficacy of warfarin in patients with atrial fibrillation on dialysis - A nationwide parallel-group open randomized clinical trial | |||||||||||||||||||||||
Medical condition: Atrial fibrillation, end-stage renal disease, and stroke | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005625-29 | Sponsor Protocol Number: VERI-305-AMIO | Start Date*: 2008-03-06 | |||||||||||
Sponsor Name:Cardiome Pharma Corp. | |||||||||||||
Full Title: A Phase III Prospective, Randomized, Double-Blind, Active-Controlled, Multi-Center, Superiority Study of Vernakalant Injection versus Amiodarone in Subjects with Recent Onset Atrial Fibrillation | |||||||||||||
Medical condition: Treatment of Atrial fibrillation (AF). AF is the most common arrhythmia encountered in clinical practice. It is usually associated with age and general physical condition, rather than with a speci... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Completed) FR (Completed) LT (Completed) EE (Completed) DK (Completed) CZ (Completed) FI (Completed) SK (Completed) LV (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002532-12 | Sponsor Protocol Number: IDE:G050233 | Start Date*: 2011-10-27 | |||||||||||
Sponsor Name:MAYO CLINIC | |||||||||||||
Full Title: Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation Trial (CABANA) | |||||||||||||
Medical condition: Atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005977-37 | Sponsor Protocol Number: 08-015 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Portola Pharmaceuticals Inc. | |||||||||||||
Full Title: A PHASE 2, RANDOMIZED, PARALLEL GROUP, DOSE-FINDING, MULTICENTER, MULTINATIONAL STUDY OF THE SAFETY, TOLERABILITY AND PILOT EFFICACY OF THREE BLINDED DOSES OF THE ORAL FACTOR Xa INHIBITOR BETRIXABA... | |||||||||||||
Medical condition: Antithrombotic treatment for prevention of stroke in patients with non-valvular atrial fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021258-20 | Sponsor Protocol Number: EAST | Start Date*: 2011-06-15 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Kompetenznetz Vorhofflimmern e.V. (AFNET) | ||||||||||||||||||||||||||||||||||||||
Full Title: Early treatment of Atrial fibrillation for Stroke prevention Trial (EAST) | ||||||||||||||||||||||||||||||||||||||
Medical condition: Atrial fibrillation, stroke, heart failure, myocardial infarction, cognitive dysfunction | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Completed) DK (Completed) NL (Completed) CZ (Completed) BE (Completed) ES (Completed) PL (Completed) IT (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-004445-17 | Sponsor Protocol Number: AP30663-2001 | Start Date*: 2021-06-29 | |||||||||||
Sponsor Name:Acesion Pharma ApS | |||||||||||||
Full Title: A Double-Blind, Randomised, Placebo-Controlled, Parallel-Group Study of AP30663 Given Intravenously for Cardioversion in Patients with Atrial Fibrillation | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002516-33 | Sponsor Protocol Number: NCT01420393 | Start Date*: 2015-09-03 |
Sponsor Name:University of Ottawa Heart Institute | ||
Full Title: A Randomized Ablation-based atrial Fibrillation rhythm control versus rate control Trial in patients with heart failure and high burden Atrial Fibrillation | ||
Medical condition: The study is comparing two accepted treatment methods (rhythm control-Catheter ablation with or without anti-arrhythmic drug control of maintaining sinus rhythm versus rate controls with medical th... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-000302-12 | Sponsor Protocol Number: BUC-CLIN-303 | Start Date*: 2016-07-13 | |||||||||||
Sponsor Name:ARCA biopharma, Inc. | |||||||||||||
Full Title: GENETIC-AF – A Genotype-Directed Comparative Effectiveness Trial of Bucindolol and Toprol-XL for Prevention of Symptomatic Atrial Fibrillation/Atrial Flutter in Patients with Heart Failure | |||||||||||||
Medical condition: Atrial Fibrillation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) NL (Completed) PL (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001723-36 | Sponsor Protocol Number: D1250C0051 | Start Date*: 2007-10-16 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A controlled, randomized, parallel, multi-centre, feasibility study of the oral direct thrombin inhibitor AZD0837, given as extended-release formulation, in the prevention of stroke and systemic em... | |||||||||||||
Medical condition: This is a phase II study to evaluate the feasibility of conducting a study in patients with AF who are appropriate for, but unable or unwilling to take VKA therapy. The intended indication for th... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
